|
Curr HIV Res: in patients with HIV-infection, chromium
supplementation improves insulin resistance and other metabolic
abnormalities: a randomized, double-blind, placebo controlled
trial.
|
|
|
|
|
| Article Type: | Brief article |
| Subject: |
Chromium (Nutrient)
(Health aspects) Chromium (Nutrient) (Research) Deficiency diseases (Complications and side effects) Deficiency diseases (Research) HIV infection (Complications and side effects) HIV infection (Research) Metabolic syndrome X (Risk factors) Metabolic syndrome X (Care and treatment) Metabolic syndrome X (Research) |
| Authors: |
Aghdassi, E. Arendt, B.M. Salit, I.E. |
| Pub Date: | 06/01/2010 |
| Publication: | Name: Alternative Medicine Review Publisher: Thorne Research Inc. Audience: Academic; Professional Format: Magazine/Journal Subject: Health Copyright: COPYRIGHT 2010 Thorne Research Inc. ISSN: 1089-5159 |
| Issue: | Date: June, 2010 Source Volume: 15 Source Issue: 2 |
| Topic: | Event Code: 310 Science & research |
| Geographic: | Geographic Scope: United States Geographic Code: 1USA United States |
|
|
|
| Accession Number: | 232175350 |
| Full Text: |
Chromium is an essential micronutrient; chromium deficiency has
been reported to cause insulin resistance, hyperglycemia and
hyperlipidemia. The aim was to investigate the effect of chromium
supplementation on insulin-resistance, other metabolic abnormalities,
and body composition in people living with HIV. This was a randomized,
double-blind, placebo-controlled trial. Fifty-two HIV-positive subjects
with elevated glucose, lipids, or evidence of body fat redistribution,
and who had insulin-resistance based on the calculation of homeostasis
model of assessment (HOMA-IR [greater than or equal to] 2.5) were
assessed. Subjects who were on insulin or hypoglycemic medications were
excluded. Subjects were randomized to receive either 400 microg/day
chromium-nicotinate or placebo for 16 weeks. Forty-six subjects, 23 in
each group, completed the study. Fasting blood insulin, glucose, lipid
profile and body composition were measured before and after
intervention. Chromium was tolerated without side effects and resulted
in a significant decrease in HOMA-IR (median (IQR) (pre:4.09
(3.02-8.79); post: 3.66 (2.40-5.46), p=0.004), insulin (pre: 102
(85-226); post: 99 (59-131) pmol/L, p=0.003), triglycerides, total body
fat mass (mean [+ or -] SEM) (pre: 17.3 [+ or -] 1.7; post: 16.3 [+ or
-] 1.7 kg; p=0.002) and trunk fat mass (pre: 23.8 [+ or -] 1.9; post:
22.7 [+ or -] 2.0%; p=0.008). Blood glucose, C-peptide, total, HDL and
LDL cholesterol, and hemoglobin Ale remained unchanged. Biochemical
parameters did not change in the placebo group except for LDL
cholesterol which increased significantly. Body weight and medication
profile remained stable throughout the study for both groups. In
summary, chromium improved insulin resistance, metabolic abnormalities,
and body composition in HIV+ patients. This suggests that chromium
supplements alleviate some of the antiretroviral- associated metabolic
abnormalities. 2010;8:113-120. |
| Gale Copyright: | Copyright 2010 Gale, Cengage Learning. All rights reserved. |